Technology ID
TAB-3493
Methods and Compositions for the Inhibition of PIN1 for the Treatment of Immune, Proliferative and Neurodegenerative Disorders
E-Numbers
E-203-2012-0
Lead Inventor
Lu, Kun Ping (Beth Israel Deaconess Medical Center)
Co-Inventors
Boxer, Matthew (NCATS)
Simeonov, Anton (NCATS)
Davis, Mindy (NCATS)
Pragani, Rajan (NCATS)
Shen, Min (NCATS)
Wei, Shuo (Beth Israel Deaconess Medical Center)
Zhou, Xiao Zhen (Beth Israel Deaconess Medical Center)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Oncology
Neurology
Lead IC
NCATS
ICs
NCATS
This technology includes the compositions and methods for inhibiting PIN1 for the treatment of disorders characterized by elevated PIN1 levels (e.g., immune disorders, proliferative disorders, and neurodegenerative disorders) with small molecules. Pin1 dysregulation has been associated with a number of pathological conditions. In particular, PIN1 has been shown to promote oncogenesis by modulating several oncogenic signaling pathways and its overexpression has been shown to correlate with poor clinical outcome. There are no current drug-like small molecule inhibitors of PIN1 that could be used therapeutically.
Commercial Applications
Inhibitors of PIN1 could be used to treat diseases such as: immune disorders, proliferative disorders, and neurodegenerative disorders.
Competitive Advantages
There are currently no drug-like small molecule inhibitors of PIN1.
Licensing Contact: